CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.19%
Annual Rate
CNY 0.25Paid unknown
Payout Ratio
23.6%Sustainable
Payback Period
97.1 yr
Last Ex-Dividend
Jun 15, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
5.09BCNY759.79M · vs all stocks (USD)
Trailing P/E
19.80xvs Biotechnology peers
Revenue (TTM)
1.44BCNY215.05M · vs all stocks (USD)
Profit Margin
14.52%vs Biotechnology peers
Beta
0.3730xvs all stocks
52-Week Change
-37.14%vs all stocks
Forward Annual Dividend Yield
1.19%vs all stocks
Market Capitalization
5.09BCNY759.79M · vs all stocks (USD)
Enterprise Value
5.02BCNY749.01M · vs all stocks (USD)
Trailing P/E
19.80xvs Biotechnology peers
Forward P/E
30.00xvs Biotechnology peers
Price to Sales (TTM)
2.94xvs Biotechnology peers
Price to Book (MRQ)
2.27xvs Biotechnology peers
Enterprise to Revenue
3.48xvs Biotechnology peers
Enterprise to EBITDA
90.66xvs Biotechnology peers
Gross Margin
50.18%vs Biotechnology peers
Profit Margin
14.52%vs Biotechnology peers
Operating Margin
-20.36%vs Biotechnology peers
Return on Assets (TTM)
-0.75%vs Biotechnology peers
Return on Equity (TTM)
11.71%vs Biotechnology peers
Revenue (TTM)
1.44BCNY215.05M · vs all stocks (USD)
Revenue per Share (TTM)
7.30CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-5.90%vs Biotechnology peers
Gross Profit (TTM)
852.39MCNY127.24M · vs all stocks (USD)
EBITDA (TTM)
239.44MCNY35.74M · vs all stocks (USD)
Net Income (TTM)
209.17MCNY31.22M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
177.30%vs Biotechnology peers
Operating Cash Flow (TTM)
81.48MCNY12.16M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-27.69MCNY-4.13M · vs all stocks (USD)
Forward Annual Dividend Rate
0.2500CNYUpdated Sep 22, 2026Forward Annual Dividend Yield
1.19%vs all stocks
Trailing Annual Dividend Rate
0.2500CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.24%vs all stocks
Payout Ratio
23.58%vs Biotechnology peers
Minority Interest (Equity)
1.51MCNYFY2025 · Dec 31, 2025Revenue
1.53BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
561.97MCNYFY2025 · Dec 31, 2025Gross Profit
972.05MCNYFY2025 · Dec 31, 2025Operating Income
97.61MCNY14.57M · vs all stocks (USD)
Pre-tax Income
165.70MCNYFY2025 · Dec 31, 2025Income Tax Expense
12.96MCNYFY2025 · Dec 31, 2025Net Income
152.74MCNYFY2025 · Dec 31, 2025EBIT
207.61MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
239.44MCNYFY2025 · Dec 31, 2025Research & Development
199.55MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
508.11MCNYFY2025 · Dec 31, 2025Other Operating Expenses
13.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
41.91MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.7900CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.7900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
196.92MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
196.92MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
152.74MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.82MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-13.74MCNYFY2025 · Dec 31, 2025Free Cash Flow
-96.20MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
648.32MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
152.74MCNYFY2025 · Dec 31, 2025Other Non-cash Items
48.91MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-224.91MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
9.52MCNYFY2025 · Dec 31, 2025Capital Expenditures
-82.46MCNYFY2025 · Dec 31, 2025Net Acquisitions
12.43MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.77BCNYFY2025 · Dec 31, 2025Sale of Investments
1.78BCNYFY2025 · Dec 31, 2025Other Investing Activity
-2.11MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-63.76MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
916.43MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-732.42MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-57.38MCNYFY2025 · Dec 31, 2025Other Financing Charges
-53.31MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
73.31MCNYFY2025 · Dec 31, 2025Shares Outstanding
201.26MSharesUpdated Sep 22, 2026Float Shares
96.29MSharesUpdated Sep 22, 2026% Held by Insiders
52.93%vs all stocks
% Held by Institutions
4.43%vs all stocks
Total Cash (MRQ)
609.87MCNY91.04M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.07CNYUpdated Sep 22, 2026Total Debt (MRQ)
1.46BCNY217.82M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.7940xvs Biotechnology peers
Current Ratio (MRQ)
1.34xvs Biotechnology peers
Book Value per Share (MRQ)
9.25CNYUpdated Sep 22, 2026Total Assets
3.53BCNY527.45M · vs all stocks (USD)
Total Current Assets
1.61BCNYFY2025 · Dec 31, 2025Total Liabilities
1.78BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.93BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
759.79MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.02BCNYFY2025 · Dec 31, 2025Cash
642.76MCNYFY2025 · Dec 31, 2025Cash Equivalents
7.67MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
650.43MCNYFY2025 · Dec 31, 2025Accounts Receivable
579.78MCNYFY2025 · Dec 31, 2025Inventory
139.22MCNYFY2025 · Dec 31, 2025Accounts Payable
229.18MCNYFY2025 · Dec 31, 2025Short-term Debt
667.24MCNYFY2025 · Dec 31, 2025Other Current Liabilities
32.61MCNYFY2025 · Dec 31, 2025Long-term Debt
729.52MCNYFY2025 · Dec 31, 2025Common Stock (Book)
201.26MCNYFY2025 · Dec 31, 2025Retained Earnings
270.70MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.75BCNY261.60M · vs all stocks (USD)
Treasury Stock
80.36MCNYFY2025 · Dec 31, 202552-Week Low
17.00CNYUpdated Sep 22, 202652-Week High
41.50CNYUpdated Sep 22, 202652-Week Change
-37.14%vs all stocks
Beta
0.3730xvs all stocks
50-Day MA
20.09CNYUpdated Sep 22, 2026200-Day MA
25.97CNYUpdated Sep 22, 2026Avg 10-Day Volume
5.18MSharesUpdated Sep 22, 2026Avg 30-Day Volume
7.95MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
1.06CNYUpdated Sep 22, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 31,222,192.102Operating Cash Flow (USD, TTM): 12,161,988.199
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.88
Altman Z-Score 2.65: safe zoneNotable
Altman Z-Score: 2.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Getein Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Olema Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
QuidelOrtho Corporation
Tier 1ProductionApproval-Gated PipelineRule
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Gyre Therapeutics Inc.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
SUNIC System Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated